Results 81 to 90 of about 6,036 (190)

Abciximab readministration: A single-operator community-hospital experience.

, 1999
Abciximab, a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor, reduces ischemic complications of coronary interventions after first administration.
Chang, K S, Arjomand, H, Magsi, Z M, Mascarenhas, D A   +3 more
core  

Grafting of abciximab to a microbubble-based ultrasound contrast agent for targeting to platelets expressing GP IIb/IIIa - characterization and in vitro testing

, 2008
Abciximab-grafted ultrasound sensitive microbubbles were developed for the diagnosis of stroke. The antibody fragment abciximab, which binds to the GP IIb/IIIa and alpha v beta 3 receptors expressed by activated platelets, was chosen because most ...
Bussat, P, Della Martina, A, Bettinger, T, Schneider, M, Lassus, A, Pochon, S, Allémann, Eric   +6 more
core   +1 more source

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction - The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

, 2003
Background-Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. However, variations
Fahy, M, Cox, DA, Turco, Mark, Mehran, R, Kandzari, David E, Stone, GW, Cox, David A, Stuckey, T, Kandzari, DE, Lansky, Alexandra J, Turco, M, Garcia, Eulogio, Grines, CL, Lansky, AJ, Garcia, E, Tcheng, JE, Griffin, JJ, Tcheng, James E, Effron, Mark B, Stuckey, Thomas, Grines, Cindy L, Fahy, Martin, Effron, MB, Stone, Gregg W, Griffin, John J, Guagliumi, Giulio, Guagliumi, G, Mehran, Roxana   +27 more
core   +1 more source

In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion

Haematologica, 2001
BACKGROUND AND OBJECTIVES: Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacologic approach with antagonists of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex.
F Rossi, E Rossi, FI Pareti, S Colli, E Tremoli, L Gallo   +5 more
doaj  

Intracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study

Heart Views, 2013
Background: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration.
Mohammed Balghith, Ali Al-Ghamdi, El harif Zain, Ahmed Al-Saileek   +3 more
doaj  

Terapias emergentes: inhibidores de glicoproteína IIB/IIIA en ataque cerebrovascular agudo

Acta Neurológica Colombiana, 2010
El ataque cerebrovascular (ACV) es una causa común de morbilidad y mortalidad en el mundo. La terapia trom- bolítica con (r-TPA), es la única terapia aprobada para el tratamiento del ACV y esta terapia solo se logra aplicar en el 2 % de los pacientes ...
Juliana Coral Casas
doaj   +2 more sources

Vergleich der intrakoronaren zur intravenösen Abciximab-Bolusgabe bei Patienten mit einem akuten Koronarsyndrom

, 2007
In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Clinical trials have studied intravenous administration only.
Schaible, Stefan
core   +1 more source

Hemorragia pulmonar por abciximab: Factores de riesgo y papel de la protamina

, 2005
Diversos ensayos clínicos han demostrado la eficacia de los inhibidores de la glucoproteína plaquetaria IIb/IIIa en un amplio espectro de pacientes con cardiopatía isquémica.
Pujol, Emilio, Sánchez, Angel, Andreu, Juan, Rodríguez-Gómez, Francisco J., Martínez, Francisco J., Alvarez, Alejandra   +5 more
core  

Paradoxical Platelet Activation Was not Observed on Dissociation of Abciximab from GPIIb-IIIa Complexes

, 2002
SummaryThe ability of abciximab to bind and dissociate from platelets raises the question of the conformational state of GPIIb-IIIa complexes losing abciximab and the risk of paradoxical drug-induced platelet activation.
Christel Poujol, Serge Ndoko, Alan Nurden, Paquita Nurden, Robert Combrié   +4 more
core   +1 more source

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention

, 2010
ObjectivesThe aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).BackgroundGlycoprotein ...
Koutouzis, Michail, Axel Åkerblom, Oldgren, Jonas, Koutouzis, Michail,, Michail Koutouzis, James, Stefan K,, Svennblad, Bodil, Stefan K. James, Stenestrand, Ulf, Stenestrand, Ulf,, Lagerqvist, Bo, Åkerblom, Axel,, Oldgren, Jonas,, Jonas Oldgren, Bodil Svennblad, Lagerqvist, Bo,, Ulf Stenestrand, James, Stefan K.,, Svennblad, Bodil,, Bo Lagerqvist, James, Stefan K, Koutouzis, Michael,, Akerblom, Axel   +22 more
core   +1 more source